143 related articles for article (PubMed ID: 2400944)
1. Introduction to 5-fluorouracil modulation.
Martin DS
Cancer Invest; 1990; 8(2):257-8. PubMed ID: 2400944
[No Abstract] [Full Text] [Related]
2. Biochemical modulation of 5-fluorouracil by PALA.
O'Dwyer PJ
Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945
[No Abstract] [Full Text] [Related]
3. Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Sotos GA; Grogan L; Allegra CJ
Cancer Treat Rev; 1994 Jan; 20(1):11-49. PubMed ID: 7507404
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.
Kemeny NE; Schneider A; Martin DS
Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946
[No Abstract] [Full Text] [Related]
5. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Köhne CH; Wilke H; Schöffski P; Schmoll HJ
J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317
[No Abstract] [Full Text] [Related]
6. Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Martin DS; Kemeny NE
Semin Oncol; 1992 Apr; 19(2 Suppl 3):49-55. PubMed ID: 1557657
[TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation as an approach to reversal of antimetabolite resistance.
O'Dwyer PJ
Cancer Treat Res; 1994; 73():201-16. PubMed ID: 7536018
[No Abstract] [Full Text] [Related]
8. Effect of modulators on 5-fluorouracil metabolite patterns in murine colon carcinoma determined by in vitro 19F nuclear magnetic resonance spectroscopy.
Kamm VJ; Rietjens IM; Vervoort J; Heerschap A; Rosenbusch G; Hofs HP; Wagener DJ
Cancer Res; 1994 Aug; 54(16):4321-6. PubMed ID: 8044779
[TBL] [Abstract][Full Text] [Related]
9. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Harte RJ; Matthews JC; O'Reilly SM; Tilsley DW; Osman S; Brown G; Luthra SJ; Brady F; Jones T; Price PM
J Clin Oncol; 1999 May; 17(5):1580-8. PubMed ID: 10334547
[TBL] [Abstract][Full Text] [Related]
10. Role of thymidine in biochemical modulation: a review.
O'Dwyer PJ; King SA; Hoth DF; Leyland-Jones B
Cancer Res; 1987 Aug; 47(15):3911-9. PubMed ID: 3300957
[TBL] [Abstract][Full Text] [Related]
11. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data.
Machover D
Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863
[No Abstract] [Full Text] [Related]
12. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Cao S; Rustum YM; Spector T
Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256
[TBL] [Abstract][Full Text] [Related]
13. Biochemical interactions between N-(phosphonacetyl)-L-aspartate and 5-fluorouracil.
Liang CM; Donehower RC; Chabner BA
Mol Pharmacol; 1982 Jan; 21(1):224-30. PubMed ID: 6813676
[No Abstract] [Full Text] [Related]
14. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
[No Abstract] [Full Text] [Related]
15. Sparfosate. A novel biomodulator of 5-fluorouracil.
Koshland P; Maa L; Ignoffo R
Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588
[No Abstract] [Full Text] [Related]
16. Pharmacological and biochemical interactions of N-(phosphonacetyl)-L-aspartate and 5-fluorouracil in beagles.
Miller AA; Moore EC; Hurlbert RB; Benvenuto JA; Loo TL
Cancer Res; 1983 Jun; 43(6):2565-70. PubMed ID: 6189583
[TBL] [Abstract][Full Text] [Related]
17. An overview of the clinical pharmacology of N-phosphonacetyl-L-aspartate (PALA), a new antimetabolite.
Erlichman C
Recent Results Cancer Res; 1980; 74():65-71. PubMed ID: 7444150
[TBL] [Abstract][Full Text] [Related]
18. Biochemical modulation: a modality that has come of therapeutic age.
Allegra CJ
J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622
[No Abstract] [Full Text] [Related]
19. Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage.
Kinsella AR; Smith D; Pickard M
Br J Cancer; 1997; 75(7):935-45. PubMed ID: 9083327
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
Kelsen D; Martin DS; Colofiore J; Sawyer R; Coit D
Cancer; 1992 Oct; 70(7):1988-92. PubMed ID: 1381991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
